Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded at StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRXFree Report) to a sell rating in a research report sent to investors on Thursday morning.

A number of other research analysts have also issued reports on LXRX. SVB Leerink started coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They issued an outperform rating and a $5.00 target price on the stock. Leerink Partnrs reaffirmed an outperform rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 30th. Finally, Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research report on Friday, May 3rd.

Check Out Our Latest Report on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $1.75 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 15.58 and a quick ratio of 15.56. The stock has a market capitalization of $430.92 million, a P/E ratio of -2.11 and a beta of 1.38. The business has a 50-day moving average of $1.80 and a two-hundred day moving average of $1.84. Lexicon Pharmaceuticals has a fifty-two week low of $0.92 and a fifty-two week high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRXGet Free Report) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Lexicon Pharmaceuticals had a negative return on equity of 108.54% and a negative net margin of 8,311.12%. The company had revenue of $1.13 million during the quarter, compared to analyst estimates of $1.17 million. On average, equities research analysts predict that Lexicon Pharmaceuticals will post -0.72 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Swiss National Bank raised its position in shares of Lexicon Pharmaceuticals by 4.4% during the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,300 shares during the last quarter. KWB Wealth acquired a new position in Lexicon Pharmaceuticals in the 4th quarter valued at approximately $62,000. China Universal Asset Management Co. Ltd. raised its holdings in Lexicon Pharmaceuticals by 350.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 22,043 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Lexicon Pharmaceuticals by 22.0% in the 4th quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 5,813 shares during the period. Finally, Principal Securities Inc. acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $33,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

(Get Free Report)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

See Also

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.